J. Shang

发表

Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors.

G. Scapin, N. Thornberry, B. Leiting, 2008, Bioorganic & medicinal chemistry letters.

(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, N. Thornberry, R. S. Roy, 2006, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2019, Bioorganic & medicinal chemistry letters.

A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery

R. Evers, F. Sistare, A. Baudy, 2020, Drug Metabolism and Disposition.

Metabolic activation of a pentafluorophenylethylamine derivative: Formation of glutathione conjugates in vitro in the rat

M. Beconi, S. Edmonson, Y. Teffera, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

S. Qureshi, S. Xu, Bei B. Zhang, 2012, Journal of medicinal chemistry.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety.

Shirly Pinto, M. Reibarkh, R. DeVita, 2019, Bioorganic & medicinal chemistry letters.

Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program.

Y. Liu, S. Hill, E. Sherer, 2016, Journal of medicinal chemistry.

Metabolic activation and major protein target of a 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonist.

Yan Zou, J. Yabut, J. Shang, 2012, Chemical research in toxicology.

Bioactivation of GPR40 Agonist MK-8666: Formation of Protein Adducts in Vitro from Reactive Acyl Glucuronide and Acyl CoA Thioester.

K. Samuel, M. Cancilla, W. Tong, 2019, Chemical research in toxicology.

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.

J. Metzger, K. Maloney, K. Rosauer, 2020, Bioorganic & medicinal chemistry letters.

STUDIES ON THE OXIDATION OF 1,4-DISUBSTITUTED-1,2,3,6-TETRAHYDROPYRIDINES

K. Castagnoli, G. Magnin, N. Castagnoli, 2002, Drug metabolism reviews.

Rat liver microsomal enzyme catalyzed oxidation of 4-phenyl-trans-1-(2-phenylcyclopropyl)-1,2,3,6-tetrahydropyridine.

N. Castagnoli, J. Shang, S. Kuttab, 2001, Bioorganic & medicinal chemistry.